Actuate Therapeutics Inc:FDA批准口服Elraglusib用于晚期癌症患者的1/2期研究新药临床试验申请

美股速递
May 11

Actuate Therapeutics Inc宣布,美国食品药品监督管理局(FDA)已批准其口服药物Elraglusib用于治疗晚期癌症患者的新药临床试验申请,该申请旨在启动一项1/2期临床研究。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10